Replies to post #138 on Fortress Biotech Inc (FBIO)

[conix]

Fortress Biotech (FBIO) Gets a Buy Rating from B.Riley Financial

April 18 2022 - 07:35AM

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Fortress Biotech (FBIO – Research Report) today and set a price target of $8.00. The company's shares closed last Thursday at $1.08, equals to its 52-week low of $1.08. According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -27.6% and a 22.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fortress Biotech with a $14.00 average price target, an 1138.